InTechOpen uses cookies to offer you the best online experience. By continuing to use our site, you agree to our Privacy Policy.

Medicine » Endocrinology and Metabolism » "Lipid Metabolism", book edited by Rodrigo Valenzuela Baez, ISBN 978-953-51-0944-0, Published: January 23, 2013 under CC BY 3.0 license. © The Author(s).

Chapter 13

Lipid Involvement in Viral Infections: Present and Future Perspectives for the Design of Antiviral Strategies

By Miguel A. Martín-Acebes, Ángela Vázquez-Calvo, Flavia Caridi, Juan-Carlos Saiz and Francisco Sobrino
DOI: 10.5772/51068

Article top


Schematic view of a virus replication cycle. For a detailed description of the different roles of lipids during virus infection see the text.
Figure 1. Schematic view of a virus replication cycle. For a detailed description of the different roles of lipids during virus infection see the text.
Distinct alterations on intracellular membrane architecture induced by the infection of positive strand RNA viruses. A) Induction of convoluted membranes and vesicle packets in flavivirus infected cells. Image corresponds to Vero cells infected with WNV, fixed and processed for transmission electron microscopy at 24 h post-infection. B) Proliferation of vesicular structures in enterovirus-infected cells. Porcine cells (IBRS-2) were infected with the enterovirus swine vesicular disease virus (SVDV), fixed, and processed for transmission electron microscopy at 7 h post-infection. For technical details related to virus infection and sample preparation see references [81,84].
Figure 2. Distinct alterations on intracellular membrane architecture induced by the infection of positive strand RNA viruses. A) Induction of convoluted membranes and vesicle packets in flavivirus infected cells. Image corresponds to Vero cells infected with WNV, fixed and processed for transmission electron microscopy at 24 h post-infection. B) Proliferation of vesicular structures in enterovirus-infected cells. Porcine cells (IBRS-2) were infected with the enterovirus swine vesicular disease virus (SVDV), fixed, and processed for transmission electron microscopy at 7 h post-infection. For technical details related to virus infection and sample preparation see references [81,84].
Virus budding through the plasma membrane. Images correspond to BHK-21 cells infected with the rhabdovirus VSV, fixed, and processed for transmission electron microscopy at 7 h post-infection. For technical details related to virus infection and sample preparation see [145].
Figure 3. Virus budding through the plasma membrane. Images correspond to BHK-21 cells infected with the rhabdovirus VSV, fixed, and processed for transmission electron microscopy at 7 h post-infection. For technical details related to virus infection and sample preparation see [145].

Lipid Involvement in Viral Infections: Present and Future Perspectives for the Design of Antiviral Strategies

Miguel A. Martín-Acebes1, Ángela Vázquez-Calvo1, Flavia Caridi1, Francisco Sobrino1 and Juan-Carlos Saiz2

1. Introduction

Viruses constitute important pathogens that can infect animals, including humans and plants. Despite their great diversity, viruses share as a common feature the dependence on host cell factors to complete their replicative cycle. Among the cellular factors required by viruses, lipids play an important role on viral infections [1-4]. The involvement of lipids in the infectious cycle is shared by enveloped viruses (those viruses whose infectious particle is wrapped by one or more lipid membranes) and non-enveloped viruses [1-4]. Apart from taking advantage on cellular lipids that are usually located inside cells, viruses induce global metabolic changes on infected cells, leading to the rearrangement of the lipid metabolism to facilitate viral multiplication [1,5-11]. In some cases, these alterations produce the reorganization of intracellular membranes of the host cell, building the adequate microenvironment for viral replication [12,13]. All these findings highlight the intimate connections between viruses and lipid metabolism. Along this line, modulation of cellular lipid metabolism to interfere with virus multiplication is currently raising as a feasible antiviral approach [6,14].

2. A lipid perspective of the virus life cycle

Inherent to their condition of obligate intracellular parasites, viruses have to invade a cell to complete their replicative cycle. During this step, viruses express their own proteins and also co-opt host cell factors for multiplication, including lipids [15]. A schematic view of a virus replication cycle is shown in Figure 1. Initial steps of viral infection include the attachment of the virus particle to a specific receptor located on the cell surface, in some cases a specific lipid (section 2.1.1). The viral genome has to entry into the host cell to reach the replication sites. Different lipids, located either on plasma and/or endosomal membranes, can contribute to these processes by enabling receptor clustering, virus internalization, or membrane fusion (sections 2.1.2 and 2.1.3). Replication of viral genome can take place associated to cellular membranes or other lipid structures, like lipid droplets, forming structures termed replication complexes (section 2.2). Newly synthesized viral genomes are enclosed inside de novo synthesized viral particles, a process in which several lipids can play, again, an important role (section 2.3), especially in the case of viruses containing a lipid envelope as an integral component of their infectious particle. Then, viral particles maturate to render infectious particles that are released from host cell to initiate a new infection cycle.


Figure 1.

Schematic view of a virus replication cycle. For a detailed description of the different roles of lipids during virus infection see the text.

2.1. Lipids and viral entry

The viral entry into a host cell to start their replicative cycle involves the attachment of the virus particle to a specific receptor(s) located on the cell surface, prior to the introduction of the viral genome within the host cell. The latter can take place by internalization of the whole viral particle, constituting a sort of minute Trojan horse [16], or by direct penetration of viral genome from plasma membrane. During these processes, a variety of specific lipids play multiple roles, which may vary between viruses (Table 1).

VSVphosphatidylserineCellular receptor[17]
LBPACofactor for membrane fusion[18,19]
SV40GM1Cellular receptor[20]
cholesterolLipid raft-caveola mediated endocytosis[21]
DENVLBPACofactor for membrane fusion[22]
VACVphosphatidylserineInduction of viral internalization[23]

Table 1.

Examples of lipids required for viral entry

2.1.1. Lipids and viral attachment

The first event of virus infection comprises the recognition of the target cell, which generally occurs through the interaction between the virus and a specific receptor on the cell surface. Receptors exploited by viruses include different macromolecules like proteins, carbohydrates and lipids. An increasing number of viruses is known to attach to lipid-containing molecules. For instance, members of the Polyomaviridae family use gangliosides, being the binding highly specific [24]. The simian virus 40 (SV40) employs exclusively the ganglioside GM1, whereas the mouse polyomavirus can use GD1a and GT1b, and BK virus can utilize GD1b and GT1b [25-28]. Other important human pathogens, such as influenza virus (Orthomyxoviridae) and Human immunodeficiency virus, HIV (Retroviridae), can also bind to different gangliosides [29,30].

Another example of a virus whose receptor is supposed to be a lipid is the rhabdovirus vesicular stomatitis virus (VSV), which seems to gain cell entry through interaction with negatively charged phospholipids, like phosphatidylserine [17]. VSV particles interact very strongly with membranes containing phosphatidylserine through viral glycoprotein G [31], and although it is not actually clear whether phosphatidylserine is the viral receptor [32], a direct interaction between the G protein and this lipid could take place in the membrane [31].

On the other hand, some members of the Flaviviridae family -hepatitis C virus (HCV), GB virus C/hepatitis G virus and bovine viral diarrhea virus (BVDV)-, use the low-density lipoprotein receptor (LDL-R) [33], which is a cholesterol receptor. An interesting case is hepatitis C virus (HCV) that requires the interaction with the low-density lipoprotein receptor (LDL-R) and with glycosaminoglycans to entry into the cell [8]. The component of the virion that interacts with LDL-R likely is a cell-derived lipoprotein, i. e. a viral-lipoprotein (section 2.3.1).

2.1.2. Lipids and viral internalization

Cells use a broad spectrum of mechanisms to internalize substances from their environment. Endocytosis is a general term for the internalization of particles, solutes, fluids, and membrane components by invagination of the plasma membrane and internalization of the resulting membrane vesicles [24,34-36]. The plasma membrane does not present a continuous or homogeneous composition. It contains lipid microdomains termed lipid rafts [37], characterized by their high content of cholesterol, glycosphinglolipids, glycophosphatidylinositol (GPI), anchored proteins like the GPI-anchored, myristoylated and palmytoylated proteins, as well as transmembrane proteins [38]. Lipid rafts have been associated with various endocytic mechanisms to internalize these membrane regions [39-42], being the formation of cave-shaped invaginations, termed caveolae, the predominant mechanism [24,34]. Lipid rafts have been related to the entry of a number of viruses, for example the coronavirus severe acute respiratory syndrome (SARS), murine leukemia virus, herpes simplex virus, Japanese encephalitis virus, SV40, and echovirus 1 [34,43-48]. In addition, some viruses require cholesterol-enriched microdomains in the viral membrane for efficient virus entry, for example influenza virus A, human herpes virus 6, and Canine distemper virus [49-51]. On the other hand, some viruses that enter into the cells using mechanisms independent of lipid rafts require cholesterol for an efficient internalization. This is the case of foot-and-mouth disease virus (FMDV) and human rhinovirus type 2, whose entry into cells, by clathrin-mediated endocytosis, requires the presence of plasma membrane cholesterol [52,53]. In other viruses such as HIV-1, a requirement of cholesterol for viral entry has been documented [47] and related to the clustering of viral receptors, thus enabling viral internalization [54]. This role of cholesterol and lipid-rafts has also been documented for coxsackievirus B3 (CVB3) infection [55].

The plasma membrane also exhibits clusters of other lipids like phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) [56], which is a minor lipid of the inner leaflet of the plasma membrane with an important role in the clathrin-mediated endocytosis [57-60]. Even when the number of viruses that use clathrin-mediated endocytosis to entry into the cells is wide [61], the importance of this lipid in viral entry has not been analyzed in depth yet. However, it has been reported that PI(4,5)P2 production by a specific lipid kinase is crucial for HIV-1 entry in permissive lymphocytes [62]. Likewise, foot-and-mouth disease virus (FMDV) and VSV require the presence of this phospholipid in the plasma membrane for internalization (Vázquez-Calvo et al., submitted).

As commented before, specific lipids located in the viral particles can also play a role on viral entry of enveloped viruses [8], including 'those located in' lipid rafts [49-51]. Vaccinia virus provides another example of the relationships between lipids located on the viral particle and viral entry. In this case, the presence of exposed phosphatidylserine in the viral envelope is critical to induce blebs on cellular membrane that promote virus internalization [23].

2.1.3. Lipids and viral genome delivery

Viruses have to release their genome from the particle to enable proper expression of viral proteins and genome replication within host cell. In the case of enveloped viruses, fusion between viral envelope and cellular membranes is a generalized strategy to facilitate these events. This process is assisted by viral proteins termed fusion proteins, and results in lipid mixing between the viral envelope and the target cellular membrane [63-66]. Viral fusion occurs either with the plasma membrane for pH-independent viruses, or, in the case of viruses entering through receptor-mediated endocytosis, with membranes of endocytic organelles in which particles are internalized. There is evidence showing that both groups of viruses use fusion proteins that, via hydrophobic segments, interact with membrane lipids, leading to conformational changes that make them able for fusion [63-66]. Compelling evidence indicates that specific lipids can influence the compartment of virus uncoating and viral genome delivery into the cytosol [22,67,68]. A number of enveloped viruses take advantage of the low pH inside endosomes to promote endosome fusion, permitting viral genome release [69]. Thus, utilization of specific lipids allows the virus to ensure membrane fusion at the proper cellular compartment. For instance, DENV takes advantage of the anionic late endosome-specific lipid bis(monoacylglycero)phosphate (BMP), also named lysobisphosphatidic acid (LBPA), to promote virus fusion with the late endosomal membrane [22]. A relevant role of LBPA in promoting membrane fusion and lipid mixing has also been shown in VSV infection [70]. Initially, VSV envelope fuses with intraluminal vesicles inside multivesicular bodies, which later fuse with external membrane of the multivesicular body, allowing the release of viral nucleocapsid to the cytosol [18,19]. However, fusion of other viruses, such as influenza virus, does not rely on these lipids [70]. Cholesterol, a major and vital constituent of eukaryotic cellular membranes, has been implicated in promoting lipid transfer and fusion pore expansion in the virus-cell membrane fusion mediated by the haemagglutinin of influenza virus [68]. The presence of cholesterol on the target membrane also promotes West Nile virus (WNV) membrane fusion activity [71], and both cholesterol and sphingolipids, but not lipid-rafts, are required for alphavirus fusion [67].

Regarding the entry of non-enveloped viruses, it is generally believed that the mechanism(s) involved does not include membrane fusion activity. Nevertheless, recent data obtained from biochemical and structural studies indicate that the overall mechanisms of entry of certain non-enveloped viruses are similar to those of enveloped ones, and that capsid proteins can function in these activities in a manner similar to that of the membrane viral proteins [72]. For instance, the outer capsid protein VP5 of the non-enveloped rotaviruses and orbiviruses, shares secondary structural features with fusion proteins of enveloped viruses [73], like the capacity to associate with lipid rafts in cellular membranes [72]. These findings indicate that VP5 may be responsible for membrane penetration [74]. Post-translational modifications of viral proteins, i.e. myristoylation of capsid protein VP4 in poliovirus (PV) and VP2 of polyomavirus, have been related to the ability of these proteins to induce pores on cellular membranes for genome release [75,76].

2.2. Lipids and viral multiplication

Following entry into the host cell, viruses have to produce accurate self-copies to generate new infectious viral particles. To this end, viruses use to recruit cellular factors, including lipids and enzymes involved in their metabolism.

2.2.1. Cellular membranes and viral replication complex assembly

Viruses co-opt host cell factors to develop the most adequate environment for their replication, a feature that is especially highlighted by the viral replication complex found assembled inside cells infected with positive strand RNA viruses [2,15,77]. Viruses belonging to this group share as a common feature a viral genome consisting of one or more RNA molecules of positive polarity that mimic the characteristics of cellular messenger RNA (mRNA) to be translated into viral proteins. Positive strand RNA viruses comprise several viral families that include important animal (including human) and plant pathogens such as Picornaviridae (i.e. PV, FMDV), Flaviviridae (i.e. DENV, WNV, HCV), Caliciviridae (i.e. Nowalk virus), Coronaviridae (i.e. SARS coronavirus), or Togaviridae (i.e. rubella virus). Replication of positive-strand RNA viruses is tightly associated to intracellular lipid membranes derived from different organelles: endoplasmic reticulum, Golgi complex, mitochondria, chloroplasts, peroxisomes, vacuoles, endosomes, or lysosomes [2]. Besides membranes derived from cellular organelles, these viruses can also usurp cytoplasmic lipid droplets for their replication [78,79]. In this way, viral replication results in the induction of marked alterations of the intracellular architecture mainly characterized by the remodelling of cellular membranes. These alterations include intracellular membrane proliferation and changes on shape and size of membranous structures. Consequently, viral replication originates a variety of structures that may rely on different mechanisms for their generation [12,15]. Examples of these structures (Figure 2) include the formation of convoluted membranes and vesicle packets as a result of flavivirus replication [80-82], the development of heterogeneous vesicular structures that conform the membranous web found in HCV-infected cells [83], or the proliferation of vesicular structures (including double membrane vesicles) in cells infected by enteroviruses (a genus within the Picornaviridae family) like PV [84,85].

Morphological changes on membrane shape induced by viral infections are accompanied by an enrichment in the viral and cellular components, including specific proteins and lipids [1-3,12]. Despite the diversity of the membrane alterations induced, these changes provide the physical scaffold for viral replication, thus offering the most suitable platform for viral replication complex assembly, and hence increasing the local concentration of specific cellular and viral factors necessary for replication [1,12]. In addition, membrane remodelling can also improve viral multiplication by hiding viral components from the innate immune system [1,12,86]. In flaviviruses (DENV and WNV) the evasion of interferon response has been shown to depend on the expression of hydrophobic viral proteins involved in membrane rearrangements [87-89]; in particular, the cholesterol content of these membranes is important to down regulate the interferon-stimulated antiviral signalling response to infection [90]. Related to this, antiviral interferon response also involves down regulation of sterol biosynthesis [91]. Likewise, lipid droplets, which can constitute platforms for viral replication, also play important roles on the coordination of immune responses [92].

All these changes in the membrane morphology and composition result in the formation of customized cellular microenvironments that support viral replication and can be actually considered novel virus-induced organelles [93-95]. Regarding the lipid composition of these structures, great progresses have been recently made (see below) that have uncovered the


Figure 2.

Distinct alterations on intracellular membrane architecture induced by the infection of positive strand RNA viruses. A) Induction of convoluted membranes and vesicle packets in flavivirus infected cells. Image corresponds to Vero cells infected with WNV, fixed and processed for transmission electron microscopy at 24 h post-infection. B) Proliferation of vesicular structures in enterovirus-infected cells. Porcine cells (IBRS-2) were infected with the enterovirus swine vesicular disease virus (SVDV), fixed, and processed for transmission electron microscopy at 7 h post-infection. For technical details related to virus infection and sample preparation see references [81,84].

dependence on different cellular lipids for replication complex organization, although their roles and importance vary between viruses.

2.2.2. Cellular lipids involved in viral replication complex assembly

To render the specific lipid microenvironment adequate for multiplication, viruses co-opt cellular machinery for their replication, including host factors involved in different aspects of lipid metabolism, i.e. sterol biosynthesis, fatty acid metabolism and synthesis of specific phosphoinositides [15]. For instance, a marked alteration of cellular metabolism and an increase in fatty acid biosynthetic pathway have been described upon human cytomegalovirus (HCMV), DENV or HCV infection [1,5,6,11]. The association of viral multiplication with modulation of host cell factors involved in lipid metabolism is not an exclusive feature of animal viruses, thus, replication and recombination of the plant pathogens tombusviruses has been revealed to rely on host genes involved in lipid metabolism [96-99]. Representative examples of cellular factors related to lipid metabolism and associated to viral replication are summarized in Table 2.

Several studies have highlighted the role of the cholesterol and the cholesterol biosynthetic pathway in the replication of viruses, including important human pathogens belonging to the Flaviviridae family -WNV [90], DENV [110], and HCV [8,111-113]- and to the Caliciviridae -Nowalk virus [114]-families. In addition, the cholesterol biosynthetic pathway has also been

VirusHost factorFunctionRefs.
BMVOle1Fatty acid desaturation[100,101]
DENVFASNFatty acid synthesis[102]
DCVSREBPFatty acid synthesis[103]
WNV3-HMG-CoA reductaseCholesterol synthesis[90]
TBSVErg25, SMO1, SMO2Sterol synthesis[104]
INO2Regulation of phospholipid synthesis[105]
HCVPI4KIIIαSynthesis of PI4P[106,107]
PV, CVB3, AiVPI4KIIIβSynthesis of PI4P[93,108,109]

Table 2.

Examples of host cell genes associated to lipid metabolism and involved in viral replication

associated to the infection of animal pathogens like African swine fever virus [115]. On the other hand, sterols have been involved in the replication of plant pathogens, for example tomato bushy stunt virus (TBSV) [104]. Due to the high diversity of viruses that exploit the cholesterol biosynthetic pathway for replication, this could consider a common requirement. However, replication of viruses may rely on lipids other than cholesterol, as described for the alphanodavirus flock house virus (FHV) [116].

Another major class of lipids that has been related to viral replication are the fatty acids, whose metabolism has been shown to be required for the multiplication of viruses such as brome mosaic virus (BMV) [100,101], Droshophila C virus (DCV) [103], CVB3 [117], and PV [118]. In some cases, in addition to the dependence of cholesterol (discussed in the previous paragraph), viral multiplication is also dependent on fatty acid synthesis. Examples of viruses sharing both cholesterol and fatty acid requirements include DENV [102], WNV [81,102], and HCV [8,112]. Indeed, during DENV infection, the key enzyme responsible for fatty acid synthesis, the fatty acid synthase (FASN), is recruited to the viral replication complex by direct interaction with the viral protein NS3, enhancing its activity [102]. Dependence of DENV replication on fatty acids is shared by mammalian and mosquito host cells [9]. Even more, DENV modulates lipid metabolism through induction of a form of autophagy that targets lipid droplet stores, promoting the depletion of cellular triglycerides and the release of fatty acids. This results on an increase in β-oxidation and ATP production that stimulate viral replication [1,5]. Infection with other viruses (HCV or CVB3) also relies on fatty acids and results in an increase on FASN expression [117,119], a phenomenon that does not occur upon DENV or WNV infection [81,102].

Besides cholesterol and fatty acids, specific phospholipids can also play a key role in viral replication. For instance, replication of TBSV and FHV is dependent on phospholipid biosynthesis [105]. Replication of FHV was initially associated to glycerophospholipids, being independent of cholesterol or sphingomyelin (a membrane phospholipid that is not derived from glycerol) [116]. However, recent advances on the biology of FHV indicate that its replication is based on the outer mitochondrial membrane and is dependent on the anionic phospholipid cardiolipin, which is almost exclusive of these membranes [120]. In this regard, more than 20 years ago, phospholipids were already associated to the replication of PV, a member of the Picornaviridae family [121]. More recently, this relationship has been confirmed after the identification of a specific phospholipid, the phosphatidylinositol 4 phosphate (PI4P), as a key component of PV replication complexes [93]. Requirement of PI4P is shared by other members of the Picornaviridae family - CVB3, Aichi virus (AiV), bovine kubovirus, and human rhinovirus 14 [93,108,109,122]- and also by viruses from other families, i.e. HCV [93,106,107,123-126]. All these viruses can specifically recruit different isoforms of the enzyme that drives the formation of PI4P from phosphatidylinositol, the phosphatidylinositol 4-kinase class III (PI4KIII) α or β, to their replication complexes. For instance, HCV recruits the lipid kinase PI4KIIIα by direct interaction with viral protein NS5A [125,127], while in picornaviruses, the recruitment of PI4KIIIβ can be mediated by the interaction of viral protein 3A with a third cellular partner associated to the viral replication complex, ABC3D (acyl-coenzyme A binding domain containing 3) [108] or other proteins implicated in the secretory pathway [93]. The dependence on either PI4KIIIα or β isoforms varies between viruses. Replication of picornaviruses is specifically associated to PI4P synthesized by PI4KIIIβ [93,108,109,122], while replication of HCV has been mainly associated to the function of PI4KIIIα [106,107], and in a lower extent to PI4KIIIβ [93,126]. In any case, PI4P is not universally required among viruses, since the replication of the flaviviruses (WNV and DENV), and the pestivirus bovine viral diarrhea virus (all members of the Flaviviridae family, like HCV) has been shown to be independent of PI4P [81,106,125].

2.2.3. Lipid functions associated to viral genome replication

The presence of specific lipids in the viral replication complex can accomplish with several missions. For instance, post-translational modification of viral proteins by lipids is associated to viral replication functions [128,129]. Table 3 displays representative examples of lipid functions during viral replication.

BMVfatty acidsIncrease in membrane plasticity and fluidity[100,101]
DENVfatty acidsEnergy production to support viral replication[5]
PVPI4PAnchor of viral replicase to replication complex[93]
FHVcardiolipinAnchor of viral replicase to replication complex[120]
HCVsphingomyelinActivation of RNA polymerase activity[130]
WNVcholesterolInnate immune evasion[90]

Table 3.

Examples of lipid roles during viral replication

Lipids can contribute to viral replication by acting as scaffolding molecules to anchor viral proteins. In PV, location of specific phospholipids (PI4P) to the viral replication sites mediates direct recruitment of the RNA dependent RNA polymerase (the enzyme that replicates the viral genome), which specifically interacts with this lipid [93]. The RNA polymerase of FHV also interacts with a specific phospholipid, the cardiolipin located on the outer mitochondrial membrane, where its replication takes place [120]. In addition to these examples, different events related to the replication of viral genomes are also influenced by specific phospholipids [131,132]. The activation of HCV replication due to a direct binding of sphingomyelin to HCV RNA polymerase has also been documented [130].

Proper topology of viral replication complexes usually depends on the induction of a membrane curvature, which may require the presence of specific proteins [133]. Membrane curvature can also be induced by modification of its lipid structure, either through changes in the polar head group or in the acyl chain composition [2,134]. Thus, during BMV infection, the function of an allele of delta9 fatty acid desaturase, an enzyme that introduces double bond in unsaturated fatty acids, has been associated to viral replication complex assembly to increase membrane fluidity and plasticity [100,101]. The accumulation of cone-shaped lipids, such as lysophospholipids, which contain single acyl chain per phospholipid molecule, and of special lipids like cholesterol or cardiolipin, has been associated with alterations on the membrane curvature and plasticity that can contribute to replication complex assembly [1,2,135].

As commented before, the membrane rearrangements resulting from replication complex assembly can also contribute to evade the cellular immune response by hiding viral components from pathogen sensors of the innate immune machinery. Thus, WNV-induced redistribution of cellular cholesterol contributes to down regulate the interferon-stimulated antiviral signalling response to infection [90].

Finally, the reorganization of cellular lipid metabolism during infection can also contribute to the generation of ATP in order to provide energy to support robust viral replication [1,5].

2.3. Lipids and viral morphogenesis

Most enveloped-viruses acquire their lipid membrane by budding through a cellular membrane that can be provided by different sources. For instance, flaviviruses (i.e. DENV or WNV) bud into the endoplasmic reticulum for acquisition of their envelope [80,82], while VSV (Figure 3), influenza, or HIV acquire their envelope by budding from plasma membrane [136-139]. In other cases, different cellular organelles can contribute with distinct membranes to virus envelopment, is reported for herpersvirus and poxvirus [140-142]. Viruses can take advantage of specific parts of the membrane for their assembly. Cholesterol and lipid raft microdomains play an important role on the assembly of a variety of viruses [136-138,143]. In HIV, the presence of PI(4,5)P2 on the membrane is also necessary for assembly and budding of viral particles, and the viral protein Gag localizes to assembly sites via the interaction with this lipid [144]. The synthesis of fatty acids has also been associated to the envelopment of viruses [6].

Other cellular lipid structures play a role on the assembly of a number of viruses. Thus, of intracellular lipid droplets have been associated with the assembly and morphogenesis


Figure 3.

Virus budding through the plasma membrane. Images correspond to BHK-21 cells infected with the rhabdovirus VSV, fixed, and processed for transmission electron microscopy at 7 h post-infection. For technical details related to virus infection and sample preparation see [145].

of DENV and HCV [78,79,146]. Assembly of HCV particles occurs on the surface of lipid droplets and, as mentioned earlier, it is related to the very low density lipoprotein (VLDL) pathway, a phenomenon that leads to the formation of unique lipo-viro-particles [4,147]. The lipoprotein component associated to HCV particles is essential for their infectivity [148], since one of its functions is to interact with LDL-R, thus contributing to viral attachment (section 2.1.1).

Lipids incorporated to viral proteins due to post-translational modifications are also involved in crucial steps of enveloped virus assembly [149,150]. Regarding morphogenesis of non-enveloped viruses, myristoylation of VP4 protein of PV and FMDV has been shown necessary for proper capsid assembly [151,152].

2.3.1. Lipid composition of enveloped viruses

Differences on the lipid composition of the viral membranes may reflect their different origin. Despite that the lipid content of enveloped viruses has been studied for decades [153-155], quantitative analyses of viral lipidomes (the entire content of lipids) at the individual molecular species level have not been possible until recently, by means of the improvement of mass spectrometry [3,139]. Following this approach, several studies have extended the knowledge on viral lipid composition. Nevertheless, drawbacks associated to the purification of cellular membranes, in particular the plasma membrane, still complicate the analysis of lipid sorting during viral budding [3].

As commented above, viral membranes can be originated from varied cellular sources (section 2.3). The lipid composition of both Semliki Forest virus (SFV) and VSV is indistinguishable and only displays slight differences with that of the plasma membrane [139]. Being SFV and VSV from different viral families (Togaviridae and Rhabdoviridae, respectively), these viruses constitute an example of little selection of the lipids included in their envelopes. Since the composition of the viral envelopes of both viruses is similar to that of the plasma membrane, the small differences observed between plasma membrane and these viral envelopes could be explained by the enrichment in specific lipids to facilitate the membrane curvature required for viral budding [139].

In the case of retroviruses (i.e. HIV and murine leukaemia virus), the overall lipid composition of viral envelopes resembles that of detergent-resistant membrane microdomains [156,157]. An enrichment in PI(4,5)P2 has also been documented in HIV envelope, which is compatible with the dependence on the interaction between the viral protein Gag and this lipid to promote HIV budding from plasma membrane [157]. Another virus that buds from membrane rafts is influenza virus [138]. The lipidome of this virus has been analyzed for viruses budding from the apical membrane of polarized cells [158]. This study revealed that that the apical cellular membrane was enriched in sphingolipids and cholesterol, whereas glycerophospholipids were reduced, and storage lipids were depleted compared with the whole-cell membranes. These results are consistent with an accumulation of lipid rafts at the membranes where the virus buds. In addition, the virus membrane exhibited a further enrichment of sphingolipids and cholesterol when compared with the donor membrane at the expense of phosphatidylcholines [158].

In other cases, major differences in lipid content between viral envelopes and host cell membranes have been found. An interesting example is the envelope of HCMV, which contains more phosphatidylethanolamines and less phosphatidylserines than the host cell membranes, resembling the synaptic vesicle lipidome [159]. Another virus with marked differences with cellular membranes is HCV, whose particles show a unique lipid composition in comparison with all other viruses analyzed to date. In addition, the lipid content of the HCV envelope is also different from that of the cells in which it was produced (cholesteryl esters comprise almost half of the total HCV lipids), resembling the composition of VLDL and LDL [160]. This finding is compatible with the association of HCV assembly with the VLDL pathway that leads to the formation of lipo-viro-particles [4,147].

3. Targeting lipid metabolism, a novel antiviral strategy

Specific lipids are essential for multiple steps of the viral replication cycle and, therefore, different strategies can be used to interfere with virus infection. As a first approach to inhibit enveloped virus multiplication, the functions of lipids incorporated into the viral particle can be targeted by chemical compounds or even by antibodies [161]. This is the case of broad-spectrum antivirals, − some of them already licensed for human use, such as arbidol [162-164] −, or inhibitors of membrane fusion [3]. Impairment of viral fusion can be achieved also by targeting viral machinery involved in this process, a strategy currently assayed for HIV treatment [165].

An alternative, non-excluding lipid-targeted strategy to prevent viral multiplication is based on inhibitors of enzymes that catalyse lipid metabolic fluxes upregulated by viral infections [6]. Examples of compounds that act at distinct points of lipid metabolism and with reported antiviral activity in vitro are given in Table 4. Targeting lipid metabolism as an antiviral strategy raises important concerns. On one hand, alteration of such important metabolic pathway for cellular homeostasis may resemble a non-specific strategy, which could result in deleterious effects for the host. However, it should be also considered that currently antiviral compounds also target other major metabolic pathways, i.e. that of nucleic acids metabolism [166-169]. On the other hand, targeting host factors to avoid viral replication could also carry advantages. Drugs that target host factors seem to be less susceptible to the development of viral resistance than strategies focused on viral proteins. Another advantage of this approach is that compounds targeting a specific group of lipids can successfully inhibit replication of different unrelated viruses (Table 4), thus constituting candidates for broad-spectrum antiviral drugs. These facts make that the use of drugs that impair different aspects of lipid metabolism has been proposed as a feasible antiviral approach [1,6,14].

Target lipidInhibitorAntiviral activity againstRefs.
CholesterolStatinsHIV, HCV, influenza[170-176]
U18666ADENV, HCV[113,177]
Fatty acidsTOFAHCMV, Influenza[6]
C75HCMV, DENV, YFV, WNV, Influenza, HCV, CVB3[6,9,81,102,117,119]
CeruleninDENV, WNV, PV, CVB3[81,102,117,121]
Oleic acidPV[118]
PI4PEnviroxime-likePV, AiV[108,109]
PIK93PV, CVB3, CVB5[81,93,109]
SphingolipidsMyriocinHepatitis B virus, HCV[180-182]
MultipleValproic acidVACV, WNV, SFV, SINV, ASFV, VSV, LCMV, USUV[145]

Table 4.

Examples of drugs targeting lipid metabolism with reported antiviral activity

3.1. Targeting cholesterol as an antiviral strategy

Cholesterol is involved in multiple steps of the viral cycle. Impairment of cholesterol biosynthetic pathway by inhibitors of 3-hydroxy-3-methyl-glutaryl-CoaA reductase (3-HMG-CoA reductase) like statins, commonly used in treatment of cardiovascular disease, constitutes a novel antiviral approach [174,175,183]. The clinical success of these inhibitors for human disorders also indicates that inhibitors of lipid metabolism can be safe and effective for human therapy. An additional effect of the treatment with statins, unrelated to the inhibition of 3-HMG-CoA reductase, is the inhibition of the binding of leukocyte function-associated antigen-1 (LFA-1) to the intercellular adhesion molecule (ICAM-1) [184], thus being immunomodulators and anti-inflammatory agents [185,186]. These properties can carry additional advantages for fighting HIV [174-176].

The infection with the paramyxovirus respiratory syncitial virus (RSV) is dependent on the isoprenylation at the carboxy terminus of the cellular protein RhoA by geranylgeranyltransferase. Lovastatin, which blocks prenylation pathways in the cell by directly inhibiting 3-HMG-CoA reductase, inhibits RSV infection both in cultured cells and in mice [183]. Treatment of patients with different statins (i.e. lovastatin, simvastin, or fluvastin) resulted in diverse effects on HCV infection, ranging from an absence of antiviral effect to a modest improvement of sustained antiviral response, or a reduction of viremia [172,173,187-189]. Beneficial effects derived from treatment with statins of infection with diverse influenza strains have also been reported in animal models and human studies [170,171], although other studies do not support these conclusions [190].

Targeting cholesterol in viral infection can be achieved using drugs other than statins, for instance U18666A. This is an intracellular cholesterol transport inhibitor widely used to block the intracellular trafficking of cholesterol and mimic Niemann-Pick type C disease, which also blocks cholesterol biosynthesis by inhibiting oxidosqualene cyclase and desmosterol reductase [191]. Treatment with U18666A inhibits DENV infection in cultured cells, and the effect of this compound is additive to the inhibitory effect of C75 (an inhibitor of FASN), which shows that both, cholesterol and fatty acids, are required for successful DENV replication [177]. U18666A also displays an antiviral effect against HCV infection and a synergistic effect has been reported when combined with interferon [113].

3.2. Inhibitors of fatty acid biosynthesis as potential antiviral compounds

The biosynthesis of fatty acids plays an important role for multiplication of a wide variety of viruses [6,9,81,102]. Pharmacological inhibition of this metabolic pathway can be achieved using 5-tetradecyloxy-2-furoic acid (TOFA), an inhibitor of acetyl-CoA carboxylase (ACC) [192]. Treatment with this compound has been shown to block replication of HCMV and influenza A virus [6]. Although the results derived from these experiments performed in model cell culture systems need to be further reproduced using animal models, the concentrations of TOFA that successfully inhibit HCMV infection in cultured cells are in the range of plasma concentrations found in rats treated with this inhibitor [6]. In HCV, treatment with TOFA attenuates the enhancement of replication of HCV induced by ethanol [193].

On the other hand, treatment with trans-4-carboxy-5-octyl-3-methylene-butyrolactone (C75) − an inhibitor of FASN, the key enzyme of fatty acid biosynthetic pathway − also resulted in inhibition of the replication of both HCMV and influenza A virus [6]. These experiments were performed in cultured cells, and the concentrations of the inhibitor tested did not induce host cell toxicity or apoptosis [6]. Similar results have been obtained for DENV, yellow fever virus (YFV), WNV, and HCV using the FASN inhibitor C75 [9,81,102,119], or cerulenin, another FASN inhibitor [81,102,111]. HMCV, influenza A, DENV, YFV, and WNV are enveloped viruses. The antiviral effect of either cerulenin or C75 has also been probed for the non-enveloped viruses CVB3 and PV [117,121], enlarging the potential antiviral spectrum of FASN inhibitors. However, it should be noted that blockage of FASN by C75 can cause severe anorexia and weight loss in animal models [194]. This makes of C75 a drug not aimed for human use, although it has aided to the identification of potential pathways to target obesity [195], and is also contributing to the understanding of the relationship between biosynthetic fatty acid synthesis and viral multiplication [6,9,81,102,117]. For DENV, a direct interaction between the viral protein NS3 and FASN has been reported [102]. Inhibition of this interaction could contribute to the design of antivirals to fight this important human disease.

Infection of HCV is intimately connected to lipid metabolism, including the fatty acid biosynthetic pathway [4,8], and its replication can be inhibited by C75 [119]. Indeed, fatty acids can either stimulate or inhibit HCV replication, depending on their degree of saturation [112]. Arachidonate, a polyunsaturated fatty acid, also inhibits HCV replication [112] via the lipid peroxidation induced by reactive oxygen species (ROS) derived from HCV replication that converts polyunsaturated fatty acids into reactive carbonyls that inactivate proteins [178]. These events can be prevented by treatment with the antioxidant vitamin E [178]. As a result of the connections between fatty acids and cholesterol biosynthetic pathways, inhibition of fatty acid synthesis can be also related to the reduction of the infection of HCV, through inhibition of the geranylgeranylation of cellular factors required for HCV replication [112,196]. The use of unsaturated fatty acids has also been applied to block myristoylation of HIV Gag protein to prevent virus budding [150].

3.3. Phosphlipids as antiviral targets

Viral replication also relies on phospholipid biosynthesis [105,121]. This makes drugs interfering this pathway candidates for antiviral design. Along this line, the antiviral properties of valproic acid - a short chain fatty acid commonly used for the treatment of epilepsy and bipolar disorder that impairs multiple aspects of phosphoinositide metabolism [197-199] - against a broad panel of enveloped viruses have been reported (Table 4) [145].

Treatment with a chimeric antibody directed against phospahtidylserine can cure arenavirus and cytomegalovirus infections in animal models [200]. The mechanism of action of this therapy is based on the exposure of phosphatidylserine on the external leaflet of the plasma membrane, a preapoptotic event in cells infected by a broad variety of viruses. The safety and pharmacokinetics of this antibody have been already evaluated in clinical trials for treatment of other human disorders [201]. Another example of the use of anti-phospholipidantibodies to combat a viral disease is provided by HIV, since different anti-phospholipid antibodies have shown a broad neutralizing activity against this virus [161].

Recent reports have highlighted the role of a specific phospholipid species, PI4P, in the replication of enteroviruses (PV, CVB3) and HCV (section 2.2.2). The synthesis of PI4P associated to viral replication relies on the function of the cellular enzymes PI4KIIIα and β. This makes both lipid kinases potential drug targets for antiviral design. An inhibitor of PI4KIIIβ, PIK93 [202], has been shown to impair replication of enteroviruses [81,93,109]. Related reports have also uncovered that this enzyme is the cellular target of known antiviral compounds against enteroviruses [109]. This is so for some enviroxime-like compounds − T-00127-HEV1 and GW5074 [93] − that integrate a group of antivirals that inhibits enterovirus replication, for which mutations conferring drug resistance mapped to the same region of the enteroviral protein 3A [109,203-205]. The recruitment of PI4KIIIβ to viral replication complexes requires the participation of cellular partners like the Golgi adaptor protein acyl coenzyme A (acyl-CoA) binding domain protein 3 (ACBD3/GPC60), as described for AiV [108,122]. In this way, modulation of the interaction between these proteins could also constitute a novel antiviral strategy [122].

In HCV infection the isoform of the enzyme involved in viral replication is mainly PI4KIIIα [106,107], although a role of the β isoform in the inhibition of HCV replication due to treatment with PIK93 has also been reported [126]. Consistent with these findings, specific compounds that successfully inhibit PV replication through blockage of PI4KIIIβ (GW5074 and T-00127-HEV1) do not affect HCV replication, although other enviroxime-like compounds can affect both enteroviral and HCV replication [109]. On the other hand, 4-anilino quinazolines were first reported to have antiviral activity against HCV, although the mechanism was not well defined. However, a recent study has associated the antiviral activity of a representative 4-anilino quinazoline (AL-9) with the inhibition of PI4KIIIα during HCV infection, which opens new therapeutic approaches [179]. Since the viral protein NS5A directly interacts with PI4KIIIα during HCV infection [125,127], modulation of this interaction also raises novel possibilities for antiviral research.

Overall, these examples of drugs targeting different enzymes related to phosphoinositide metabolism support this strategy as a feasible approach for antiviral drug discovery. In this line, related phosphoinositide kinases constitute an important emerging class of drug targets [202].

3.4. Sphingolipids as antiviral targets

Sphingolipids constitute a major component of lipid rafts [37,38], which, as commented before, are involved in different steps of viral infection, making sphingolipids potential antiviral targets. Along this line, ebolavirus requires the activity of acid sphingomyelinase, the enzyme that converts sphingomyelin to phosphocholine and ceramide for infection, and depletion of sphingomyelin reduces its infection [206]. A dependence on sphingomyelin for HCV replication has also been documented [130]. Inhibition of serine palmitoyltransferase, the enzyme that catalyzes the first step on sphingolipid biosynthesis, using myriocin has also been assayed against HCV or hepatitis B virus, either alone or in combination with interferon [180-182]. However, a certain controversy exists regarding whether the inhibitory effect of myriocin on HCV replication is attributable to the specific inhibition of serine palmitoyltransferase, since FTY720, a compound that like myriocin is structurally similar to sphingosine but does not inhibit serine palmitoyltransferase, also inhibits HCV replication [207].

4. Conclusion

The analysis of the functions of cellular factors in viral infections has highlighted the role of different lipid species in these infections. Viruses can use cellular lipids like bricks to build viral particles or to develop viral replication complexes, thus facilitating its multiplication. But viruses can also manipulate host cell metabolism towards the production of specific lipid species, unveiling an intimate relationship between viruses and host cell lipid metabolism. Indeed, great progresses have been recently made in this area due to the identification of specific lipids as key factors for viral multiplication. However, the specific function of most of these lipids remains to be determined. A better understanding of the interactions between viral infections and lipid metabolism is desirable to asses the roles of lipids in viral multiplication. This knowledge could lead to the identification of lipid targets and druggable metabolic pathways suitable for antiviral development. Lipid candidates for these interventions have already been identified, for instance fatty acids, cholesterol or specific phospholipids. Indeed, initial lipid-based antiviral approaches have been already started, even at clinical level (i.e. statins). This example has probed that drugs already licensed for humans that act at different points of lipid metabolism can constitute potential candidates to fight viral diseases. These lipid-targeted antiviral approaches could be exclusive or could also be complementary to other antiviral therapies already available.

As recently remarked, ‘if RNA ruled the last decade and DNA dominated the previous one, could the next decade be the one for lipids?’ [208]. The new advances on the knowledge of the interplay between viruses and lipids evidence that the answer to this question could be ‘Yes’ in the case of virology [1]. Hopefully, we are now assisting to the promising birth of a novel lipid-based branch of antiviral research focused on this challenging and still poorly explored field for drug discovery.


Work at CBMSO was supported by grants from Ministerio de Ciencia e Innovación (MICINN, Spain) BIO2008-0447-C03-01, and BIO2011-24351, and by an institutional grant from the “Fundación Ramón Areces”.

Work at INIA was supported by grants RTA2011-00036 from the Spanish Ministerio de Ciencia e Innovación (MICINN) and the Network of Animal Disease Infectiology and Research-European Union NADIR-EU-228394. MAMA is the recipient of a JAE-Doc fellowship from Spanish Research Council (CSIC).


1 - N. S Heaton, G Randall, 2011Multifaceted roles for lipids in viral infectionTrends Microbiol 19368375
2 - K. A Stapleford, D. J Miller, 2010Role of cellular lipids in positive-sense RNA virus replication complex assembly and function.Viruses210551068
3 - M Lorizate, H. G Krausslich, 2011Role of lipids in virus replication.Cold Spring Harb Perspect Biol 3: a004820 EOF
4 - G Alvisi, V Madan, R Bartenschlager, 2011Hepatitis C virus and host cell lipids: an intimate connection.RNA Biol 8258269
5 - N. S Heaton, G Randall, 2010Dengue virus-induced autophagy regulates lipid metabolismCell Host Microbe 8422432
6 - J Munger, B. D Bennett, A Parikh, X. J Feng, J Mcardle, H. A Rabitz, T Shenk, J. D Rabinowitz, 2008Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapyNat Biotechnol 2611791186
7 - S Blackham, A Baillie, F Al-hababi, K Remlinger, S You, R Hamatake, M. J Mcgarvey, 2010Gene expression profiling indicates the roles of host oxidative stress, apoptosis, lipid metabolism, and intracellular transport genes in the replication of hepatitis C virus. JVirol 8454045414
8 - P Targett-adams, S Boulant, M. W Douglas, J Mclauchlan, 2010Lipid metabolism and HCV infectionViruses 211951217
9 - R Perera, C Riley, G Isaac, A. S Hopf-jannasch, R. J Moore, K. W Weitz, L Pasa-tolic, T. O Metz, J Adamec, R. J Kuhn, 2012Dengue virus infection perturbs lipid homeostasis in infected mosquito cells. PLoS Pathog 8: e1002584.
10 - M. A Rodgers, A Saghatelian, P. L Yang, 2009Identification of an overabundant cholesterol precursor in hepatitis B virus replicating cells by untargeted lipid metabolite profilingJ Am Chem Soc 13150305031
11 - D. L Diamond, A. J Syder, J. M Jacobs, C. M Sorensen, K. A Walters, S. C Proll, J. E Mcdermott, M. A Gritsenko, Q Zhang, R Zhao, T. O Metz, D. G Camp, nd, Waters KM, Smith RD, Rice CM, Katze MG (2010Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog 6: e1000719.
12 - S Miller, J Krijnse-locker, 2008Modification of intracellular membrane structures for virus replicationNat Rev Microbiol 6363374
13 - den Boon JADiaz A, Ahlquist 2010Cytoplasmic viral replication complexesCell Host Microbe 8: 77-85.
14 - M. F Bassendine, D. A Sheridan, D. J Felmlee, S. H Bridge, G. L Toms, R. D Neely, 2011HCV and the hepatic lipid pathway as a potential treatment targetJ Hepatol 5514281440
15 - P. D Nagy, J Pogany, 2012The dependence of viral RNA replication on co-opted host factors.Nat Rev Microbiol 10137149
16 - K Sandvig, B Van Deurs, 2008Cell biology: Viruses in camouflageNature453466467
17 - R Schlegel, T. S Tralka, M. C Willingham, I Pastan, 1983Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell 32639646
18 - H Matsuo, J Chevallier, N Mayran, Le Blanc I, Ferguson C, Faure J, Blanc NS, Matile S, Dubochet J, Sadoul R, Parton RG, Vilbois F, Gruenberg J (2004Role of LBPA and Alix in multivesicular liposome formation and endosome organization. Science 303531534
19 - Le Blanc ILuyet PP, Pons V, Ferguson C, Emans N, Petiot A, Mayran N, Demaurex N, Faure J, Sadoul R, Parton RG, Gruenberg J (2005Endosome-to-cytosol transport of viral nucleocapsids. Nat Cell Biol 7653664
20 - M. A Campanero-rhodes, A Smith, W Chai, S Sonnino, L Mauri, R. A Childs, Y Zhang, H Ewers, A Helenius, A Imberty, T Feizi, 2007N-glycolyl GM1 ganglioside as a receptor for simian virus 40. J Virol 811284612858
21 - H. A Anderson, Y Chen, L. C Norkin, 1996Bound simian virus 40 translocates to caveolin-enriched membrane domains, and its entry is inhibited by drugs that selectively disrupt caveolae.Mol Biol Cell 718251834
22 - E Zaitseva, S. T Yang, K Melikov, S Pourmal, Chernomordik LV Dengue virus ensures its fusion in late endosomes using compartment-specific lipids. PLoS Pathog 6: e1001131.
23 - J Mercer, A Helenius, 2008Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cellsScience320531535
24 - H Ewers, A Helenius, 2011Lipid-mediated endocytosis.Cold Spring Harb Perspect Biol 3: a004721 EOF
25 - J. A Low, B Magnuson, B Tsai, M. J Imperiale, 2006Identification of gangliosides GD1b and GT1b as receptors for BK virusJ Virol 8013611366
26 - B Tsai, J. M Gilbert, T Stehle, W Lencer, T. L Benjamin, T. A Rapoport, 2003Gangliosides are receptors for murine polyoma virus and SV40Embo J 2243464355
27 - T. G Magaldi, M. H Buch, H Murata, K. D Erickson, U Neu, R. L Garcea, K Peden, T Stehle, D Dimaio, 2012Mutations in the GM1 Binding Site of SV40 VP1 Alter Receptor Usage and Cell Tropism. J Virol.
28 - B Tsai, M Qian, 2010Cellular entry of polyomaviruses.Curr Top Microbiol Immunol 343177194
29 - I Meisen, T Dzudzek, C Ehrhardt, S Ludwig, M Mormann, R Rosenbruck, R Lumen, B Kniep, H Karch, J Muthing, 2012The human H3N2 influenza viruses A/Victoria/3/75 and A/Hiroshima/52/2005 preferentially bind to alpha23sialylated monosialogangliosides with fucosylated poly-N-acetyllactosaminyl chains. Glycobiology.
30 - N Izquierdo-useros, M Lorizate, F. X Contreras, M. T Rodriguez-plata, B Glass, I Erkizia, J. G Prado, J Casas, G Fabrias, H. G Krausslich, J Martinez-picado, 2012Sialyllactose in Viral Membrane Gangliosides Is a Novel Molecular Recognition Pattern for Mature Dendritic Cell Capture of HIV-1.PLoS Biol 10: e1001315 EOF
31 - F. A Carneiro, P. A Lapido-loureiro, S. M Cordo, F Stauffer, G Weissmuller, M. L Bianconi, M. A Juliano, L Juliano, P. M Bisch, Da Poian AT (2006Probing the interaction between vesicular stomatitis virus and phosphatidylserine. Eur Biophys J 35145154
32 - D. A Coil, A. D Miller, 2004Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virusJ Virol 781092010926
33 - V Agnello, G Abel, M Elfahal, G. B Knight, Q. X Zhang, 1999Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptorProc Natl Acad Sci U S A 961276612771
34 - M Marsh, A Helenius, 2006Virus entry: open sesameCell124729740
35 - S. D Conner, S. L Schmid, 2003Regulated portals of entry into the cell.Nature4223744
36 - S Mayor, R. E Pagano, 2007Pathways of clathrin-independent endocytosis.Nat Rev Mol Cell Biol 8603612
37 - K Simons, E Ikonen, 1997Functional rafts in cell membranes.Nature387569572
38 - K Jacobson, O. G Mouritsen, R. G Anderson, 2007Lipid rafts: at a crossroad between cell biology and physics.Nat Cell Biol 9714
39 - D. J Chinnapen, H Chinnapen, D Saslowsky, W. I Lencer, 2007Rafting with cholera toxin: endocytosis and trafficking from plasma membrane to ER. FEMS Microbiol Lett 266129137
40 - F Martin-belmonte, J. A Martinez-menarguez, J. F Aranda, J Ballesta, M. C De Marco, M. A Alonso, 2003MAL regulates clathrin-mediated endocytosis at the apical surface of Madin-Darby canine kidney cells.J Cell Biol 163155164
41 - R Rollason, V Korolchuk, C Hamilton, P Schu, G Banting, 2007Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif.J Cell Sci 12038503858
42 - A Stoddart, M. L Dykstra, B. K Brown, W Song, S. K Pierce, F. M Brodsky, 2002Lipid rafts unite signaling cascades with clathrin to regulate BCR internalization.Immunity17451462
43 - F. C Bender, J. C Whitbeck, Ponce de Leon M, Lou H, Eisenberg RJ, Cohen GH (2003Specific association of glycoprotein B with lipid rafts during herpes simplex virus entryJ Virol 7795429552
44 - E. M Damm, L Pelkmans, J Kartenbeck, A Mezzacasa, T Kurzchalia, A Helenius, 2005Clathrin- and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae.J Cell Biol 168477488
45 - S Das, S Chakraborty, Basu A Critical role of lipid rafts in virus entry and activation of phosphoinositide 3’ kinase/Akt signaling during early stages of Japanese encephalitis virus infection in neural stem/progenitor cells. J Neurochem 115537549
46 - J Glende, C Schwegmann-wessels, M Al-falah, S Pfefferle, X Qu, H Deng, C Drosten, H. Y Naim, G Herrler, 2008Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2Virology381215221
47 - Z Liao, L. M Cimakasky, R Hampton, D. H Nguyen, J. E Hildreth, 2001Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1AIDS Res Hum Retroviruses 1710091019
48 - X Lu, Y Xiong, J Silver, 2002Asymmetric requirement for cholesterol in receptor-bearing but not envelope-bearing membranes for fusion mediated by ecotropic murine leukemia virus.J Virol 7667016709
49 - H Huang, Y Li, T Sadaoka, H Tang, T Yamamoto, K Yamanishi, Y Mori, 2006Human herpesvirus 6 envelope cholesterol is required for virus entry.J Gen Virol 87277285
50 - H Imhoff, V Von Messling, G Herrler, L Haas, 2007Canine distemper virus infection requires cholesterol in the viral envelope.J Virol 8141584165
51 - X Sun, G. R Whittaker, 2003Role for influenza virus envelope cholesterol in virus entry and infectionJ Virol 771254312551
52 - M. A Martin-acebes, M Gonzalez-magaldi, K Sandvig, F Sobrino, R Armas-portela, 2007Productive entry of type C foot-and-mouth disease virus into susceptible cultured cells requires clathrin and is dependent on the presence of plasma membrane cholesterolVirology369105118
53 - L Snyers, H Zwickl, D Blaas, 2003Human rhinovirus type 2 is internalized by clathrin-mediated endocytosis.J Virol 7753605369
54 - L Yi, J Fang, N Isik, J Chim, T Jin, 2006HIV gp120-induced interaction between CD4 and CCR5 requires cholesterol-rich microenvironments revealed by live cell fluorescence resonance energy transfer imaging.J Biol Chem 2813544635453
55 - C. B Coyne, J. M Bergelson, 2006Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctionsCell124119131
56 - K Kwiatkowska, 2010One lipid, multiple functions: how various pools of PI(4,5)2are created in the plasma membrane. Cell Mol Life Sci 67: 3927-3946.
57 - C. N Antonescu, F Aguet, G Danuser, S. L Schmid, 2011Phosphatidylinositol-(4,5)-bisphosphate regulates clathrin-coated pit initiation, stabilization, and size. Mol Biol Cell 2225882600
58 - M. A De Matteis, A Godi, 2004PI-loting membrane traffic.Nat Cell Biol 6487492
59 - D. J James, C Khodthong, J. A Kowalchyk, T. F Martin, 2008Phosphatidylinositol 4,5-bisphosphate regulates SNARE-dependent membrane fusion. J Cell Biol 182355366
60 - R Zoncu, R. M Perera, R Sebastian, F Nakatsu, H Chen, T Balla, G Ayala, D Toomre, P. V De Camilli, 2007Loss of endocytic clathrin-coated pits upon acute depletion of phosphatidylinositol 4,5-bisphosphateProc Natl Acad Sci U S A 10437933798
61 - J Mercer, M Schelhaas, A Helenius, 2010Virus entry by endocytosisAnnu Rev Biochem 79803833
62 - M Barrero-villar, J Barroso-gonzalez, J. R Cabrero, M Gordon-alonso, S Alvarez-losada, M. A Munoz-fernandez, F Sanchez-madrid, A Valenzuela-fernandez, 2008PI45Ialpha is required for efficient HIV-1 entry and infection of T cells.J Immunol 181: 6882-6888.
63 - E Teissier, E. I Pecheur, 2007Lipids as modulators of membrane fusion mediated by viral fusion proteinsEur Biophys J 36887899
64 - S. C Harrison, 2008Viral membrane fusionNat Struct Mol Biol 15690698
65 - A Puri, M Paternostre, R Blumenthal, 2002Lipids in viral fusion.Methods Mol Biol 1996181
66 - F. A Rey, 2006Molecular gymnastics at the herpesvirus surfaceEMBO Rep 710001005
67 - M Kielian, C Chanel-vos, M Liao, 2010Alphavirus Entry and Membrane FusionViruses 2796825
68 - S Biswas, S. R Yin, P. S Blank, J Zimmerberg, 2008Cholesterol promotes hemifusion and pore widening in membrane fusion induced by influenza hemagglutininJ Gen Physiol 131503513
69 - A Vazquez-calvo, J. C Saiz, K. C Mccullough, F Sobrino, M. A Martin-acebes, 2012Acid-dependent viral entry. Virus Res. In press
70 - S. L Roth, G. R Whittaker, 2011Promotion of vesicular stomatitis virus fusion by the endosome-specific phospholipid bis(monoacylglycero)phosphate (BMP). FEBS Lett 585865869
71 - B Moesker, I. A Rodenhuis-zybert, T Meijerhof, J Wilschut, J. M Smit, 2010Characterization of the functional requirements of West Nile virus membrane fusionJ Gen Virol 91389393
72 - B Bhattacharya, P Roy, 2010Role of lipids on entry and exit of bluetongue virus, a complex non-enveloped virusViruses 212181235
73 - S. D Trask, K. M Guglielmi, J. T Patton, 2010Primed for Discovery: Atomic-Resolution Cryo-EM Structure of a Reovirus Entry Intermediate.Viruses213401346
74 - S. H Hassan, C Wirblich, M Forzan, P Roy, 2001Expression and functional characterization of bluetongue virus VP5 protein: role in cellular permeabilizationJ Virol 7583568367
75 - P Danthi, M Tosteson, Q. H Li, M Chow, 2003Genome delivery and ion channel properties are altered in VP4 mutants of poliovirusJ Virol 7752665274
76 - N Krauzewicz, C. H Streuli, N Stuart-smith, M. D Jones, S Wallace, B. E Griffin, 1990Myristylated polyomavirus VP2: role in the life cycle of the virus.J Virol 6444144420
77 - J Mackenzie, 2005Wrapping things up about virus RNA replicationTraffic 6967977
78 - M. M Samsa, J. A Mondotte, N. G Iglesias, I Assuncao-miranda, G Barbosa-lima, Da Poian AT, Bozza PT, Gamarnik AV (2009Dengue virus capsid protein usurps lipid droplets for viral particle formation. PLoS Pathog 5: e1000632.
79 - Y Miyanari, K Atsuzawa, N Usuda, K Watashi, T Hishiki, M Zayas, R Bartenschlager, T Wakita, M Hijikata, K Shimotohno, 2007The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 910891097
80 - S Welsch, S Miller, I Romero-brey, A Merz, C. K Bleck, P Walther, S. D Fuller, C Antony, J Krijnse-locker, R Bartenschlager, 2009Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe 5365375
81 - M. A Martin-acebes, A. B Blazquez, Jimenez de Oya N, Escribano-Romero E, Saiz JC (2011West nile virus replication requires Fatty Acid synthesis but is independent on phosphatidylinositol-4phosphate lipids.PLoS Onee24970.
82 - J. M Mackenzie, E. G Westaway, 2001Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively.J Virol 751078710799
83 - D Moradpour, R Gosert, D Egger, F Penin, H. E Blum, K Bienz, 2003Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex.Antiviral Res 60103109
84 - M. A Martin-acebes, M Gonzalez-magaldi, M. F Rosas, B Borrego, E Brocchi, R Armas-portela, F Sobrino, 2008Subcellular distribution of swine vesicular disease virus proteins and alterations induced in infected cells: a comparative study with foot-and-mouth disease virus and vesicular stomatitis virusVirology374432443
85 - D. A Suhy, T. H Giddings, Jr., Kirkegaard K (2000Remodeling the endoplasmic reticulum by poliovirus infection and by individual viral proteins: an autophagy-like origin for virus-induced vesicles.J Virol 7489538965
86 - A Hoenen, W Liu, G Kochs, A. A Khromykh, J. M Mackenzie, 2007West Nile virus-induced cytoplasmic membrane structures provide partial protection against the interferon-induced antiviral MxA protein.J Gen Virol 8830133017
87 - R. L Ambrose, J. M Mackenzie, 2011West Nile virus differentially modulates the unfolded protein response to facilitate replication and immune evasion. JVirol 8527232732
88 - J. L Munoz-jordan, M Laurent-rolle, J Ashour, L Martinez-sobrido, M Ashok, W. I Lipkin, A Garcia-sastre, 2005Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses.J Virol 7980048013
89 - J. L Munoz-jordan, G. G Sanchez-burgos, M Laurent-rolle, A Garcia-sastre, 2003Inhibition of interferon signaling by dengue virus.Proc Natl Acad Sci U S A 1001433314338
90 - J. M Mackenzie, A. A Khromykh, R. G Parton, 2007Cholesterol manipulation by West Nile virus perturbs the cellular immune responseCell Host Microbe 2229239
91 - M Blanc, W. Y Hsieh, K. A Robertson, S Watterson, G Shui, P Lacaze, M Khondoker, P Dickinson, G Sing, S Rodriguez-martin, P Phelan, T Forster, B Strobl, M Muller, R Riemersma, T Osborne, M. R Wenk, A Angulo, P Ghazal, 2011Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLoS Biol 9: e1000598.
92 - H. A Saka, R. H Valdivia, 2012Emerging Roles for Lipid Droplets in Immunity and Host-Pathogen Interactions.Annu Rev Cell Dev Biol.
93 - N. Y Hsu, O Ilnytska, G Belov, M Santiana, Y. H Chen, P. M Takvorian, C Pau, H Van Der Schaar, N Kaushik-basu, T Balla, C. E Cameron, E Ehrenfeld, F. J Van Kuppeveld, N Altan-bonnet, 2010Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141799811
94 - den Boon JAAhlquist 2010Organelle-like membrane compartmentalization of positive-strand RNA virus replication factoriesAnnu Rev Microbiol 64: 241-256.
95 - B. G Kopek, G Perkins, D. J Miller, M. H Ellisman, P Ahlquist, 2007Three-dimensional analysis of a viral RNA replication complex reveals a virus-induced mini-organelle.PLoS Biol 5: e220 EOF
96 - Y Jiang, E Serviene, J Gal, T Panavas, P. D Nagy, 2006Identification of essential host factors affecting tombusvirus RNA replication based on the yeast Tet promoters Hughes Collection.J Virol 8073947404
97 - E Serviene, Y Jiang, C. P Cheng, J Baker, P. D Nagy, 2006Screening of the yeast yTHC collection identifies essential host factors affecting tombusvirus RNA recombinationJ Virol 8012311241
98 - T Panavas, E Serviene, J Brasher, P. D Nagy, 2005Yeast genome-wide screen reveals dissimilar sets of host genes affecting replication of RNA viruses.Proc Natl Acad Sci U S A 10273267331
99 - E Serviene, N Shapka, C. P Cheng, T Panavas, B Phuangrat, J Baker, P. D Nagy, 2005Genome-wide screen identifies host genes affecting viral RNA recombination.Proc Natl Acad Sci U S A 1021054510550
100 - W. M Lee, P Ahlquist, 2003Membrane synthesis, specific lipid requirements, and localized lipid composition changes associated with a positive-strand RNA virus RNA replication protein. J Virol 771281912828
101 - W. M Lee, M Ishikawa, P Ahlquist, 2001Mutation of host delta9 fatty acid desaturase inhibits brome mosaic virus RNA replication between template recognition and RNA synthesis.J Virol 7520972106
102 - N. S Heaton, R Perera, K. L Berger, S Khadka, D. J Lacount, R. J Kuhn, G Randall, 2010Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesisProc Natl Acad Sci U S A 1071734517350
103 - S Cherry, A Kunte, H Wang, C Coyne, R. B Rawson, N Perrimon, 2006COPI activity coupled with fatty acid biosynthesis is required for viral replicationPLoS Pathog 2: e102.
104 - M Sharma, Z Sasvari, P. D Nagy, 2010Inhibition of sterol biosynthesis reduces tombusvirus replication in yeast and plantsJ Virol 8422702281
105 - M Sharma, Z Sasvari, P. D Nagy, 2011Inhibition of phospholipid biosynthesis decreases the activity of the tombusvirus replicase and alters the subcellular localization of replication proteinsVirology415141152
106 - F. H Vaillancourt, L Pilote, M Cartier, J Lippens, M Liuzzi, R. C Bethell, M. G Cordingley, G Kukolj, 2009Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replicationVirology387510
107 - K. L Berger, J. D Cooper, N. S Heaton, R Yoon, T. E Oakland, T. X Jordan, G Mateu, A Grakoui, G Randall, 2009Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replicationProc Natl Acad Sci U S A 10675777582
108 - J Sasaki, K Ishikawa, M Arita, K Taniguchi, 2011ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication sites.Embo J 31754766
109 - M Arita, H Kojima, T Nagano, T Okabe, T Wakita, H Shimizu, 2011Phosphatidylinositol-4 kinase III beta is a target of enviroxime-like compounds for anti-poliovirus activity. J Virol 8523642372
110 - C Rothwell, A Lebreton, Young Ng C, Lim JY, Liu W, Vasudevan S, Labow M, Gu F, Gaither LA (2009Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 389819
111 - S. M Sagan, Y Rouleau, C Leggiadro, L Supekova, P. G Schultz, A. I Su, J. P Pezacki, 2006The influence of cholesterol and lipid metabolism on host cell structure and hepatitis C virus replication.Biochem Cell Biol 846779
112 - S. B Kapadia, F. V Chisari, 2005Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acidsProc Natl Acad Sci U S A 10225612566
113 - T Takano, K Tsukiyama-kohara, M Hayashi, Y Hirata, M Satoh, Y Tokunaga, C Tateno, Y Hayashi, T Hishima, N Funata, M Sudoh, M Kohara, 2011Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes. J Hepatol 55512521
114 - K. O Chang, 2009Role of cholesterol pathways in norovirus replicationJ Virol 8385878595
115 - J. I Quetglas, B Hernaez, I Galindo, R Munoz-moreno, M. A Cuesta-geijo, Alonso C Small rho GTPases and cholesterol biosynthetic pathway intermediates in African swine fever virus infection. J Virol 8617581767
116 - S. X Wu, P Ahlquist, P Kaesberg, 1992Active complete in vitro replication of nodavirus RNA requires glycerophospholipid.Proc Natl Acad Sci U S A 891113611140
117 - A Rassmann, A Henke, N Jarasch, F Lottspeich, H. P Saluz, T Munder, 2007The human fatty acid synthase: a new therapeutic target for coxsackievirus B3-induced diseases? Antiviral Res 76150158
118 - R Guinea, L Carrasco, 1991Effects of fatty acids on lipid synthesis and viral RNA replication in poliovirus-infected cells.Virology185473476
119 - W Yang, B. L Hood, S. L Chadwick, S Liu, S. C Watkins, G Luo, T. P Conrads, T Wang, 2008Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and productionHepatology4813961403
120 - K. A Stapleford, D Rapaport, D. J Miller, 2009Mitochondrion-enriched anionic phospholipids facilitate flock house virus RNA polymerase membrane associationJ Virol 8344984507
121 - R Guinea, L Carrasco, 1990Phospholipid biosynthesis and poliovirus genome replication, two coupled phenomena.Embo J 920112016
122 - A. L Greninger, G. M Knudsen, M Betegon, A. L Burlingame, J. L Derisi, 2012The 3A protein from multiple picornaviruses utilizes the golgi adaptor protein ACBD3 to recruit PI4KIIIbeta. J Virol 8636053616
123 - A. W Tai, Y Benita, L. F Peng, S. S Kim, N Sakamoto, R. J Xavier, R. T Chung, 2009A functional genomic screen identifies cellular cofactors of hepatitis C virus replicationCell Host Microbe 5298307
124 - A. W Tai, S Salloum, 2011The role of the phosphatidylinositol 4kinase PI4KA in hepatitis C virus-induced host membrane rearrangement.PLoS Onee26300.
125 - S Reiss, I Rebhan, P Backes, I Romero-brey, H Erfle, P Matula, L Kaderali, M Poenisch, H Blankenburg, M. S Hiet, T Longerich, S Diehl, F Ramirez, T Balla, K Rohr, A Kaul, S Buhler, R Pepperkok, T Lengauer, M Albrecht, R Eils, P Schirmacher, V Lohmann, R Bartenschlager, 2011Recruitment and Activation of a Lipid Kinase by Hepatitis C Virus NS5A Is Essential for Integrity of the Membranous Replication Compartment. Cell Host Microbe 93245
126 - J Borawski, P Troke, X Puyang, V Gibaja, S Zhao, C Mickanin, J Leighton-davies, C. J Wilson, V Myer, I Cornellataracido, J Baryza, J Tallarico, G Joberty, M Bantscheff, M Schirle, T Bouwmeester, J. E Mathy, K Lin, T Compton, M Labow, B Wiedmann, L. A Gaither, 2009Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J Virol 831005810074
127 - Y. S Lim, S. B Hwang, 2011Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation.J Biol Chem 2861129011298
128 - I Levental, M Grzybek, K Simons, 2010Greasing their way: lipid modifications determine protein association with membrane raftsBiochemistry4963056316
129 - G. Y Yu, K. J Lee, L Gao, M. M Lai, 2006Palmitoylation and polymerization of hepatitis C virus NS4B proteinJ Virol 8060136023
130 - L Weng, Y Hirata, M Arai, M Kohara, T Wakita, K Watashi, K Shimotohno, Y He, J Zhong, T Toyoda, 2010Sphingomyelin activates hepatitis C virus RNA polymerase in a genotype-specific manner. J Virol 841176111770
131 - T Ahola, A Lampio, P Auvinen, L Kaariainen, 1999Semliki Forest virus mRNA capping enzyme requires association with anionic membrane phospholipids for activity.Embo J 1831643172
132 - K Saito, M Nishijima, O Kuge, 2006Phosphatidylserine is involved in gene expression from Sindbis virus subgenomic promoterBiochem Biophys Res Commun 345878885
133 - T. R Graham, M. M Kozlov, 2010Interplay of proteins and lipids in generating membrane curvatureCurr Opin Cell Biol 22430436
134 - J. A Szule, N. L Fuller, R. P Rand, 2002The effects of acyl chain length and saturation of diacylglycerols and phosphatidylcholines on membrane monolayer curvature.Biophys J 83977984
135 - N Fuller, R. P Rand, 2001The influence of lysolipids on the spontaneous curvature and bending elasticity of phospholipid membranes.Biophys J 81243254
136 - A Ono, 2010Relationships between plasma membrane microdomains and HIV-1 assemblyBiol Cell 102335350
137 - A. A Waheed, E. O Freed, 2010The Role of Lipids in Retrovirus ReplicationViruses 211461180
138 - D. P Nayak, R. A Balogun, H Yamada, Z. H Zhou, S Barman, 2009Influenza virus morphogenesis and budding. Virus Res 143147161
139 - L Kalvodova, J. L Sampaio, S Cordo, C. S Ejsing, A Shevchenko, K Simons, 2009The lipidomes of vesicular stomatitis virus, semliki forest virus, and the host plasma membrane analyzed by quantitative shotgun mass spectrometry. J Virol 8379968003
140 - T. C Mettenleiter, B. G Klupp, H Granzow, 2009Herpesvirus assembly: an update. Virus Res 143222234
141 - R. C Condit, N Moussatche, P Traktman, 2006In a nutshell: structure and assembly of the vaccinia virion. Adv Virus Res 6631124
142 - B Sodeik, J Krijnse-locker, 2002Assembly of vaccinia virus revisited: de novo membrane synthesis or acquisition from the host? Trends Microbiol 101524
143 - N Chazal, D Gerlier, 2003Virus entry, assembly, budding, and membrane rafts. Microbiol Mol Biol Rev 67226237table of contents.
144 - R. H Ghanam, A. B Samal, T. F Fernandez, J. S Saad, 2012Role of the HIV-1 Matrix Protein in Gag Intracellular Trafficking and Targeting to the Plasma Membrane for Virus Assembly. Front Microbiol 3: 55.
145 - A Vazquez-calvo, J. C Saiz, F Sobrino, M. A Martin-acebes, 2011Inhibition of enveloped virus infection of cultured cells by valproic Acid. J Virol 8512671274
146 - P Roingeard, C Hourioux, E Blanchard, G Prensier, 2008Hepatitis C virus budding at lipid droplet-associated ER membrane visualized by 3D electron microscopy. Histochem Cell Biol 130561566
147 - R Bartenschlager, F Penin, V Lohmann, P Andre, 2011Assembly of infectious hepatitis C virus particles. Trends Microbiol 1995103
148 - Y Shimizu, T Hishiki, S Ujino, K Sugiyama, K Funami, K Shimotohno, 2011Lipoprotein component associated with hepatitis C virus is essential for virus infectivity. Curr Opin Virol 11926
149 - N Majeau, R Fromentin, C Savard, M Duval, M. J Tremblay, D Leclerc, 2009Palmitoylation of hepatitis C virus core protein is important for virion production. J Biol Chem 2843391533925
150 - O. W Lindwasser, M. D Resh, 2002Myristoylation as a target for inhibiting HIV assembly: unsaturated fatty acids block viral budding. Proc Natl Acad Sci U S A 991303713042
151 - N Moscufo, J Simons, M Chow, 1991Myristoylation is important at multiple stages in poliovirus assembly. J Virol 6523722380
152 - S Goodwin, T. J Tuthill, A Arias, R. A Killington, D. J Rowlands, 2009Foot-and-mouth disease virus assembly: processing of recombinant capsid precursor by exogenous protease induces self-assembly of pentamers in vitro in a myristoylation-dependent manner. J Virol 831127511282
153 - R. C Aloia, F. C Jensen, C. C Curtain, P. W Mobley, L. M Gordon, 1988Lipid composition and fluidity of the human immunodeficiency virus. Proc Natl Acad Sci U S A 85900904
154 - C. B Hirschberg, P. W Robbins, 1974The glycolipids and phospholipids of Sindbis virus and their relation to the lipids of the host cell plasma membrane. Virology 61602608
155 - H. D Klenk, P. W Choppin, 1971Glycolipid content of vesicular stomatitis virus grown in baby hamster kidney cells. J Virol 7416417
156 - B Brugger, B Glass, P Haberkant, I Leibrecht, F. T Wieland, H. G Krausslich, 2006The HIV lipidome: a raft with an unusual composition. Proc Natl Acad Sci U S A 10326412646
157 - R Chan, P. D Uchil, J Jin, G Shui, D. E Ott, W Mothes, M. R Wenk, 2008Retroviruses human immunodeficiency virus and murine leukemia virus are enriched in phosphoinositides. J Virol 821122811238
158 - M. J Gerl, J. L Sampaio, S Urban, L Kalvodova, J. M Verbavatz, B Binnington, D Lindemann, C. A Lingwood, A Shevchenko, C Schroeder, K Simons, 2012Quantitative analysis of the lipidomes of the influenza virus envelope and MDCK cell apical membrane. J Cell Biol 196213221
159 - S. T Liu, R Sharon-friling, P Ivanova, S. B Milne, D. S Myers, J. D Rabinowitz, H. A Brown, T Shenk, 2011Synaptic vesicle-like lipidome of human cytomegalovirus virions reveals a role for SNARE machinery in virion egress. Proc Natl Acad Sci U S A 1081286912874
160 - A Merz, G Long, M. S Hiet, B Brugger, P Chlanda, P Andre, F Wieland, J Krijnse-locker, R Bartenschlager, 2011Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 28630183032
161 - M. A Moody, H. X Liao, S. M Alam, R. M Scearce, M. K Plonk, D. M Kozink, M. S Drinker, R Zhang, S. M Xia, L. L Sutherland, G. D Tomaras, I. P Giles, J. C Kappes, C Ochsenbauer-jambor, T. G Edmonds, M Soares, G Barbero, D. N Forthal, G Landucci, C Chang, S. W King, A Kavlie, T. N Denny, K. K Hwang, P. P Chen, P. E Thorpe, D. C Montefiori, B. F Haynes, 2010Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med 207763776
162 - E Teissier, G Zandomeneghi, A Loquet, D Lavillette, J. P Lavergne, R Montserret, F. L Cosset, A Bockmann, B. H Meier, F Penin, E. I Pecheur, 2011Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One 6: e15874.
163 - Y. S Boriskin, I. A Leneva, E. I Pecheur, S. J Polyak, 2008Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 159971005
164 - M. C Wolf, A. N Freiberg, T Zhang, Z Akyol-ataman, A Grock, P. W Hong, J Li, N. F Watson, A. Q Fang, H. C Aguilar, M Porotto, A. N Honko, R Damoiseaux, J. P Miller, S. E Woodson, S Chantasirivisal, V Fontanes, O. A Negrete, P Krogstad, A Dasgupta, A Moscona, L. E Hensley, S. P Whelan, K. F Faull, M. R Holbrook, M. E Jung, B Lee, 2010A Broad-spectrum, antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A 10731573162
165 - B Berkhout, D Eggink, R. W Sanders, 2012Is there a future for antiviral fusion inhibitors? Curr Opin Virol 25059
166 - G Andrei, E De Clercq, R Snoeck, 2008Novel inhibitors of human CMV. Curr Opin Investig Drugs 9132145
167 - J. D Graci, C. E Cameron, 2006Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 163748
168 - E De Clercq, 2009The history of antiretrovirals: key discoveries over the past 25 years. Rev Med Virol 19287299
169 - S Olschlager, J Neyts, S Gunther, 2011Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antiviral Res 918993
170 - Z Liu, Z Guo, G Wang, D Zhang, H He, G Li, Y Liu, D Higgins, A Walsh, L Shanahan-prendergast, J Lu, 2009Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur J Pharm Sci 38215223
171 - S. J Brett, P Myles, W. S Lim, J. E Enstone, B Bannister, M. G Semple, R. C Read, B. L Taylor, J Mcmenamin, K. G Nicholson, J. S Nguyen-van-tam, P. J Openshaw, 2011Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One 6: e18120.
172 - R Mihaila, L Nedelcu, O Fratila, E. C Rezi, C Domnariu, R Ciuca, A. V Zaharie, A Olteanu, L Bera, M Deac, 2009Lovastatin and fluvastatin reduce viremia and the pro-inflammatory cytokines in the patients with chronic hepatitis C. Hepatogastroenterology 5617041709
173 - T Bader, J Fazili, M Madhoun, C Aston, D Hughes, S Rizvi, K Seres, M Hasan, 2008Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 10313831389
174 - C Gilbert, M Bergeron, S Methot, J. F Giguere, M. J Tremblay, 2005Statins could be used to control replication of some viruses, including HIV-1. Viral Immunol 18474489
175 - J. F Giguere, M. J Tremblay, 2004Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 781206212065
176 - C. J Montoya, F Jaimes, E. A Higuita, S Convers-paez, S Estrada, F Gutierrez, P Amariles, N Giraldo, C Penaloza, M. T Rugeles, 2009Antiretroviral effect of lovastatin on HIV-1infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial. Trials 10: 41.
177 - M. K Poh, G Shui, X Xie, P. Y Shi, M. R Wenk, F Gu, 2012U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication. Antiviral Res 93191198
178 - H Huang, Y Chen, J Ye, 2007Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. Proc Natl Acad Sci U S A 1041866618670
179 - A Bianco, V Reghellin, L Donnici, S Fenu, R Alvarez, C Baruffa, F Peri, M Pagani, S Abrignani, P Neddermann, R De Francesco, 2012Metabolism of phosphatidylinositol 4kinase IIIalpha-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity. PLoS Pathog 8: e1002576.
180 - K Tatematsu, Y Tanaka, M Sugiyama, M Sudoh, M Mizokami, 2011Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B virus replication. J Med Virol 83587593
181 - T Umehara, M Sudoh, F Yasui, C Matsuda, Y Hayashi, K Chayama, M Kohara, 2006Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem Biophys Res Commun 3466773
182 - F Amemiya, S Maekawa, Y Itakura, A Kanayama, A Matsui, S Takano, T Yamaguchi, J Itakura, T Kitamura, T Inoue, M Sakamoto, K Yamauchi, S Okada, A Yamashita, N Sakamoto, M Itoh, N Enomoto, 2008Targeting lipid metabolism in the treatment of hepatitis C virus infection. J Infect Dis 197361370
183 - T. L Gower, B. S Graham, 2001Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother 4512311237
184 - G Weitz-schmidt, K Welzenbach, V Brinkmann, T Kamata, J Kallen, C Bruns, S Cottens, Y Takada, U Hommel, 2001Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7687692
185 - G Weitz-schmidt, 2003Lymphocyte function-associated antigen-1 blockade by statins: molecular basis and biological relevance. Endothelium 104347
186 - G Weitz-schmidt, 2002Statins as anti-inflammatory agents. Trends Pharmacol Sci 23482486
187 - S. A Harrison, L Rossaro, K. Q Hu, K Patel, H Tillmann, S Dhaliwal, D. M Torres, K Koury, V. S Goteti, S Noviello, C. A Brass, J. K Albrecht, J. G Mchutchison, M. S Sulkowski, 2010Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 52864874
188 - R. G Mihaila, L Nedelcu, O Fratila, L Retzler, C Domnariu, R. C Cipaian, E. C Rezi, C Beca, M Deac, 2011Effects of simvastatin in patients with viral chronic hepatitis C. Hepatogastroenterology 5812961300
189 - K Patel, S. G Lim, C. W Cheng, E Lawitz, H. L Tillmann, N Chopra, R Altmeyer, J. C Randle, J. G Mchutchison, 2011Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. Antivir Ther 1613411346
190 - J. C Kwong, P Li, D. A Redelmeier, 2009Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS One 4: e8087.
191 - R. J Cenedella, 2009Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids 44477487
192 - D. L Halvorson, S. A Mccune, 1984Inhibition of fatty acid synthesis in isolated adipocytes by 5-(tetradecyloxy)-2-furoic acid. Lipids 19851856
193 - S Seronello, C Ito, T Wakita, J Choi, 2010Ethanol enhances hepatitis C virus replication through lipid metabolism and elevated NADH/NAD+. J Biol Chem 285845854
194 - T. M Loftus, D. E Jaworsky, G. L Frehywot, C. A Townsend, G. V Ronnett, M. D Lane, F. P Kuhajda, 2000Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 28823792381
195 - F. P Kuhajda, L. E Landree, G. V Ronnett, 2005The connections between C75 and obesity drug-target pathways. Trends Pharmacol Sci 26541544
196 - C Wang, M Gale, Jr., Keller BC, Huang H, Brown MS, Goldstein JL, Ye J (2005Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 18425434
197 - G Shaltiel, A Shamir, J Shapiro, D Ding, E Dalton, M Bialer, A. J Harwood, R. H Belmaker, M. L Greenberg, G Agam, 2004Valproate decreases inositol biosynthesis. Biol Psychiatry 56868874
198 - S. M Tokuoka, A Saiardi, S. J Nurrish, 2008The mood stabilizer valproate inhibits both inositol- and diacylglycerol-signaling pathways in Caenorhabditis elegans. Mol Biol Cell 1922412250
199 - X Xu, A Muller-taubenberger, K. E Adley, N Pawolleck, V. W Lee, C Wiedemann, T. S Sihra, M Maniak, T Jin, R. S Williams, 2007Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot Cell 6899906
200 - M. M Soares, S. W King, P. E Thorpe, 2008Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 1413571362
201 - D. E Gerber, A. T Stopeck, L Wong, L. S Rosen, P. E Thorpe, J. S Shan, N. K Ibrahim, 2011Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 1768886896
202 - Z. A Knight, B Gonzalez, M. E Feldman, E. R Zunder, D. D Goldenberg, O Williams, R Loewith, D Stokoe, A Balla, B Toth, T Balla, W. A Weiss, R. L Williams, K. M Shokat, 2006A pharmacological map of the PI3-K family defines a role for 110alphain insulin signaling. Cell 125: 733-747.
203 - M Arita, T Wakita, H Shimizu, 2009Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J Gen Virol 9018691879
204 - A. M De Palma, H. J Thibaut, L Van Der Linden, K Lanke, W Heggermont, S Ireland, R Andrews, M Arimilli, T. H Al-tel, E De Clercq, F Van Kuppeveld, J Neyts, 2009Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother 5318501857
205 - B. A Heinz, L. M Vance, 1995The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol 6941894197
206 - M. E Miller, S Adhikary, A. A Kolokoltsov, R. A Davey, 2012Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. J Virol. 8674737483
207 - S Ciesek, E Steinmann, M. P Manns, H Wedemeyer, T Pietschmann, 2008The suppressive effect that myriocin has on hepatitis C virus RNA replication is independent of inhibition of serine palmitoyl transferase. J Infect Dis 19810911093
208 - M Doucleff, 2010Select: Lipids out loud. Cell 143853855